NO20073487L - Valg av pasienter for terapi med en HER-inhibitor - Google Patents
Valg av pasienter for terapi med en HER-inhibitorInfo
- Publication number
- NO20073487L NO20073487L NO20073487A NO20073487A NO20073487L NO 20073487 L NO20073487 L NO 20073487L NO 20073487 A NO20073487 A NO 20073487A NO 20073487 A NO20073487 A NO 20073487A NO 20073487 L NO20073487 L NO 20073487L
- Authority
- NO
- Norway
- Prior art keywords
- therapy
- inhibitor
- selecting patients
- gene expression
- expression analysis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63394104P | 2004-12-07 | 2004-12-07 | |
PCT/US2005/044247 WO2006063042A2 (en) | 2004-12-07 | 2005-12-06 | Selecting patients for therapy with a her inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073487L true NO20073487L (no) | 2007-09-05 |
Family
ID=36177671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073487A NO20073487L (no) | 2004-12-07 | 2007-07-05 | Valg av pasienter for terapi med en HER-inhibitor |
Country Status (14)
Country | Link |
---|---|
US (2) | US20060121044A1 (de) |
EP (1) | EP1825001A2 (de) |
JP (1) | JP2008523073A (de) |
KR (1) | KR20070085855A (de) |
CN (1) | CN101115849A (de) |
AR (1) | AR051524A1 (de) |
AU (1) | AU2005314127A1 (de) |
BR (1) | BRPI0518086A (de) |
CA (1) | CA2587519A1 (de) |
MX (1) | MX2007006529A (de) |
NO (1) | NO20073487L (de) |
RU (1) | RU2007125644A (de) |
WO (1) | WO2006063042A2 (de) |
ZA (1) | ZA200704796B (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
DK1282443T3 (da) | 2000-05-19 | 2010-01-04 | Genentech Inc | Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
JP2008507520A (ja) | 2004-07-22 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Her2抗体組成物 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
ZA200704796B (en) * | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
CN103251946A (zh) * | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
JP2007135581A (ja) * | 2005-10-20 | 2007-06-07 | Japan Science & Technology Agency | 自己免疫性血小板減少性紫斑病(itp)患者の血液細胞特異的遺伝子群 |
AU2007259171A1 (en) * | 2006-06-05 | 2007-12-21 | F. Hoffmann-La Roche, Ag | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
JP5656406B2 (ja) * | 2006-11-28 | 2015-01-21 | ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングU3 Pharma GmbH | 治療効力を予測するためのマーカーとしての活性化her3 |
US7825127B2 (en) * | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
MX338185B (es) * | 2007-01-25 | 2016-04-05 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
SI2132573T1 (sl) * | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
ES2583377T3 (es) * | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
EP2188311B1 (de) | 2007-08-14 | 2016-10-05 | Ludwig Institute for Cancer Research Ltd. | Auf den egf-rezeptor zielender, monoklonaler antikörper 175 und derivate und anwendungen davon |
WO2009026705A1 (en) * | 2007-08-24 | 2009-03-05 | The University Of Western Ontario | Method of diagnosing and treating osteoarthritis |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
EP2313780B1 (de) | 2008-07-08 | 2015-05-20 | George Mason Research Foundation, Inc. | Phosphoryliertes c-erbb2 als besserer theranostischer vorhersagemarker für die diagnose und behandlung von krebs |
WO2010051502A2 (en) | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
EP2513148B1 (de) * | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2-antikörper und ihre verwendung |
DK2544680T3 (en) | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー/エス | Her2エピトープに対するモノクローナル抗体 |
CN107253992B (zh) | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
JP6186277B2 (ja) | 2010-11-01 | 2017-08-23 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 抗her3抗体および組成物 |
CA2832389A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
WO2013052745A1 (en) * | 2011-10-06 | 2013-04-11 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
AU2012322797B2 (en) | 2011-10-14 | 2016-04-21 | Genentech, Inc. | Uses for and article of manufacture including HER2 dimerization inhibitor Pertuzumab |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
ES2759061T3 (es) * | 2013-03-15 | 2020-05-07 | Biomolecular Holdings Llc | Inmunoglobulina híbrida que contiene unión no peptidílica |
CN105121471A (zh) | 2013-04-16 | 2015-12-02 | 豪夫迈·罗氏有限公司 | 帕妥珠单抗变体及其评估 |
EP3087394A2 (de) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien |
HRP20221233T1 (hr) | 2014-03-14 | 2022-12-09 | Biomolecular Holdings Llc | Spojevi korisni u pripravi hibridnog imunoglobina koji sadrži nepeptidilnu vezu |
WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
JP6524266B2 (ja) * | 2015-05-29 | 2019-06-05 | エクスプレッション、パソロジー、インコーポレイテッドExpression Pathology, Inc. | 最適な癌療法のためのHer2タンパク質の定量化 |
JP6822980B2 (ja) | 2015-05-30 | 2021-01-27 | ジェネンテック, インコーポレイテッド | Her2陽性転移性乳癌の治療方法 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
GB201611580D0 (en) * | 2016-07-01 | 2016-08-17 | Aslan Pharmaceuticals Pte Ltd | Method |
AU2017355432A1 (en) | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
CN110167594B (zh) | 2017-01-17 | 2023-11-21 | 豪夫迈·罗氏有限公司 | 皮下her2抗体配制剂 |
KR20230144110A (ko) | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
EP3615695A1 (de) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2-mutationen in der transmembran- oder juxtamembran-domäne |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5824311A (en) * | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US6407213B1 (en) * | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
JP2002507404A (ja) * | 1998-03-27 | 2002-03-12 | ジェネンテク・インコーポレイテッド | Apo−2リガンド−抗HER−2抗体相乗作用 |
DE69936946T2 (de) * | 1998-05-06 | 2008-05-15 | Genentech, Inc., South San Francisco | Reinigung von Antikörpern durch Ionenaustauschchromatographie |
US6573043B1 (en) * | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
WO2000069460A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
CH694589A5 (de) * | 1999-06-25 | 2005-04-15 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. |
CA2383493C (en) * | 1999-06-25 | 2010-08-10 | Genentech, Inc. | Treating prostate cancer with anti-erbb2 antibodies |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) * | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
NZ517150A (en) * | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
DK1282443T3 (da) * | 2000-05-19 | 2010-01-04 | Genentech Inc | Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi |
US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
DK2263691T3 (da) * | 2002-07-15 | 2012-10-22 | Hoffmann La Roche | Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4) |
US20040013297A1 (en) * | 2002-07-18 | 2004-01-22 | Roger Lo | Method for performing color gamut compression |
WO2004035803A2 (en) * | 2002-10-01 | 2004-04-29 | Epigenomics Ag | Method and nucleic acids for the treatment of breast cell proliferative disorders |
JP4606879B2 (ja) * | 2002-11-15 | 2011-01-05 | ジェノミック ヘルス, インコーポレイテッド | Egfr陽性癌の遺伝子発現プロファイリング |
EP1572972A4 (de) * | 2002-11-21 | 2007-11-21 | Genentech Inc | Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
DK1641810T4 (en) * | 2003-06-24 | 2017-07-03 | Genomic Health Inc | Predicting the likelihood of cancer recurrence |
JP4969440B2 (ja) * | 2004-04-08 | 2012-07-04 | デビッド, ビー. エイガス, | 疼痛治療のためのErbBアンタゴニスト |
SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
JP2008507520A (ja) * | 2004-07-22 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Her2抗体組成物 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
ZA200704796B (en) * | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
CN102580084B (zh) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
CN103251946A (zh) * | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
AU2007259171A1 (en) * | 2006-06-05 | 2007-12-21 | F. Hoffmann-La Roche, Ag | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
DK2056874T3 (da) * | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
-
2005
- 2005-12-06 ZA ZA200704796A patent/ZA200704796B/xx unknown
- 2005-12-06 EP EP05853228A patent/EP1825001A2/de not_active Withdrawn
- 2005-12-06 BR BRPI0518086-4A patent/BRPI0518086A/pt not_active IP Right Cessation
- 2005-12-06 WO PCT/US2005/044247 patent/WO2006063042A2/en active Application Filing
- 2005-12-06 JP JP2007545584A patent/JP2008523073A/ja active Pending
- 2005-12-06 CA CA002587519A patent/CA2587519A1/en not_active Abandoned
- 2005-12-06 MX MX2007006529A patent/MX2007006529A/es not_active Application Discontinuation
- 2005-12-06 RU RU2007125644/13A patent/RU2007125644A/ru not_active Application Discontinuation
- 2005-12-06 US US11/295,229 patent/US20060121044A1/en not_active Abandoned
- 2005-12-06 KR KR1020077012834A patent/KR20070085855A/ko not_active Application Discontinuation
- 2005-12-06 CN CNA2005800478629A patent/CN101115849A/zh active Pending
- 2005-12-06 AU AU2005314127A patent/AU2005314127A1/en not_active Abandoned
- 2005-12-07 AR ARP050105126A patent/AR051524A1/es not_active Application Discontinuation
-
2007
- 2007-07-05 NO NO20073487A patent/NO20073487L/no not_active Application Discontinuation
-
2008
- 2008-05-01 US US12/113,802 patent/US20080317753A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20070085855A (ko) | 2007-08-27 |
CA2587519A1 (en) | 2006-06-15 |
WO2006063042A3 (en) | 2007-02-08 |
BRPI0518086A (pt) | 2008-10-28 |
EP1825001A2 (de) | 2007-08-29 |
JP2008523073A (ja) | 2008-07-03 |
ZA200704796B (en) | 2008-11-26 |
MX2007006529A (es) | 2007-06-22 |
AU2005314127A1 (en) | 2006-06-15 |
RU2007125644A (ru) | 2009-01-20 |
US20060121044A1 (en) | 2006-06-08 |
AR051524A1 (es) | 2007-01-17 |
CN101115849A (zh) | 2008-01-30 |
WO2006063042A2 (en) | 2006-06-15 |
US20080317753A1 (en) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20073487L (no) | Valg av pasienter for terapi med en HER-inhibitor | |
NO20080371L (no) | Fremgangsmate for a forutsi responsen overfor en behandling | |
NO20080622L (no) | Disykloalkylurea-glukokinase aktivatorer | |
NO20075865L (no) | Innelukket behandlingskjemikalie og fremgangsmate for forsinket frigivelse av samme | |
ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
NI200900061A (es) | Composiciones y métodos para la modulación de los receptores c-kit y pdgf. | |
ATE514755T1 (de) | Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung | |
TW200800989A (en) | Pyrrolopyridine kinase inhibiting compounds | |
NO20072290L (no) | Organiske forbindelser. | |
NO20056236L (no) | Behandling med anti-VEGF-antistoffer | |
MY147410A (en) | Compounds and methods for kinase modulation, and indications therefor | |
IN2014DN02241A (de) | ||
NO20082386L (no) | Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav | |
NO20054359L (no) | Cykliske protein tyrosin kinase inhibitorer | |
NO20092023L (no) | Oligoribonuleotider og anvendelser derav | |
WO2010031056A3 (en) | Methods and compositions for modulating ire1, src, and abl activity | |
NO20053765L (no) | Heisanlegg med en heisstol og en innretning for bestemmelse av en heisstolposisjon, samt fremgangsmate for drift av et slikt heisanlegg. | |
BRPI0516727A (pt) | métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença | |
NO20075706L (no) | Pyrrolopyridinbaserte inhibitorer av dipeptidylpeptidase IV og metoder | |
EP2114990A4 (de) | Mit der therapeutischen wirkung von egfr-tk-hemmern assoziierte gen- und proteinexpressionsprofile | |
NO20081045L (no) | Forbindelser og fremgangsmater for behandling av cancer | |
MX2018011625A (es) | Metodos para detectar bordetella. | |
PT1529116E (pt) | Métodos para o tratamento da demência com base no genótipo da apo e | |
CY1116166T1 (el) | Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori | |
WO2008059041A3 (en) | Complementation of factor xi deficiency by factor v mutants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |